XM does not provide services to residents of the United States of America.
A
A

Agilent

News

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds: Mattel, Tellurian Updates: Clearwater Paper, Agilent July 22 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1955 GMT on Monday: * * L Catterton, the private equity firm backed by luxury goods giant LVMH LVMH.PA , has approached Mattel MAT.O , the toy maker behind Barbie and Hot Wheels, with an acquisition offer, people familiar with the matter said.
A
G
H
L
M
V
D

Agilent Technologies To Acquire BIOVECTRA for $925 Million

BRIEF-Agilent Technologies To Acquire BIOVECTRA for $925 Million July 22 (Reuters) - Agilent Technologies Inc A.N : AGILENT TO ACQUIRE NORTH AMERICAN CDMO BIOVECTRA AGILENT TECHNOLOGIES INC - TO ACQUIRE BIOVECTRA FOR $925 MILLION AGILENT TECHNOLOGIES INC - EXPECTS ACQUISITION TO BE $0.05 DILUTIVE TO NON-GAAP EPS Source text for Eikon: ID:nBw5TcW1Fa
A

Agilent to buy contract drug manufacturer Biovectra for $925 mln

UPDATE 2-Agilent to buy contract drug manufacturer Biovectra for $925 mln Adds deal details in paragraph 5 and background throughout July 22 (Reuters) - Agilent Technologies A.N said on Monday it will acquire contract drug manufacturer Biovectra for $925 million to expand its portfolio of services offered to biotech companies and medical researchers.
A

Agilent to buy contract drug manufacturer Biovectra for $925 million

Agilent to buy contract drug manufacturer Biovectra for $925 million July 22 (Reuters) - Medical equipment maker Agilent Technologies A.N said on Monday it will acquire privately held contract drug manufacturer Biovectra for $925 million. Reporting by Mariam Sunny in Bengaluru; Editing by Shounak Dasgupta
A

U.S. Elevance Health, J&J, Primerica

U.S. RESEARCH ROUNDUP-Elevance Health, J&J, Primerica July 18 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Elevance Health, J&J and Primerica, on Thursday. HIGHLIGHTS * Elevance Health Inc ELV.N : Leerink Partners cuts target price to $620 from $630 * J&J JNJ.N : TD Cowen cuts target price to $185 from $195 * Primerica Inc PRI.N : Jefferies raises target price to $249 from $239 * Travelers Companies Inc TRV.N : HS
A
A
O
P
Q
A
A
C

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.